Loading
Phibro Animal Health Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jun 2026.
Phibro Animal Health Corp: what insiders have been doing
This page follows insider dealings at Phibro Animal Health Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 16 insiders published 86 filings.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €274k) and 51 sales (1 insider, €12.2M). Sales outweigh purchases by €11.9M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive. One trade stands out by size: a sale of €2.2M from Bendheim Jack, disclosed on 11 February 2026.
The last purchase on record was published on 2 June 2026, which is 137 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,458 companies, median 22 filings), a count of 86 filings is above the norm. Looking back to 2016, when coverage begins, insiders filed 4 purchases and 84 sales. For the fiscal year to 30 June 2026, the annual 10-K puts revenue at 1.52 bn USD and net income at 99.7 m USD, and the dividend at 0.48 USD per share.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
149
Thresholds
n/a
Buy Volume
€569,735
4 ops. · all time
Sell Volume
€14M
84 ops. · all time
Who traded when
BuySaleJack Bendheim54 sales
E. Thomas Corcoran2 buys
Since the insiders bought
- +20.7%Entry US$31.79 · Close at T+90 US$38.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,809 of 24,148 companies
58.2
score / 100
Value58
Quality59
FCF yld0.6%
Earn yld6.5%
EV/EBITDA10.0x
ROE30%
Gross mgn34%
Net mgn6.6%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$37.98
Analyst consensus
4 analysts3.00/5
US$35.00Target US$44.00(+16%)US$55.00
Income statement
RevenueUS$1.5B
Gross profitUS$512.5M34% margin
EBITDAUS$233M15% margin
Net incomeUS$99.7M6.6% margin
Valuation
PER (trailing)15.2x
PER (forward)9.9x
P/Book4.0x
Beta0.42
Balance sheet & cash
Market capUS$1.5B
Total debtUS$788.8M
Free Cash FlowUS$9.9M
Debt / Equity206%
Profitability & ownership
ROE29.7%
ROA8.5%
% insiders0.9%
% institutions104.0%
Last declaration on 17 September 2026
Declarations149 total
3,726 shares0Class A Common StockSEC:0001104659-26-108617:0
3,482 shares0Class A Common StockSEC:0001104659-26-108618:0
350,000 shares@ US$35.300.88% mcap58.1% of flowClass A Common StockSEC144:0001958244-26-000611
3,334 shares0Class A Common StockSEC:0001104659-26-093394:0
1,547 shares0Class A Common StockSEC:0001104659-26-093383:0
3,522 shares0Class A Common StockSEC:0001104659-26-093391:0
2,478 shares0Class A Common StockSEC:0001104659-26-093387:0
1,503 shares0Class A Common StockSEC:0001104659-26-093397:0
12,103 shares0Class A Common StockSEC:0001104659-26-093385:0
2,716 shares0Class A Common StockSEC:0001104659-26-093388:0
11,699 shares0Class A Common StockSEC:0001104659-26-093378:0
2,303 shares@ US$36.5990.0060% mcap0.5% of flowClass A Common StockSEC:0001104659-26-092233:0
486 shares@ US$36.5990.0013% mcap50.0% of flowClass A Common StockSEC:0001104659-26-092227:0
840 shares@ US$36.5990.0022% mcap50.0% of flowClass A Common StockSEC:0001104659-26-092228:0
265 shares@ US$36.5990.0007% mcap50.0% of flowClass A Common StockSEC:0001104659-26-092232:0
635 shares@ US$36.5990.0017% mcap50.0% of flowClass A Common StockSEC:0001104659-26-092230:0
472 shares@ US$36.5990.0012% mcap50.0% of flowClass A Common StockSEC:0001104659-26-092229:0
2,303 shares@ US$36.59940.0060% mcap0.5% of flowClass ASEC144:0001959173-26-005612
840 shares@ US$36.59940.0022% mcap50.0% of flowClass ASEC144:0001959173-26-005613
635 shares@ US$36.59940.0017% mcap50.0% of flowClass ASEC144:0001959173-26-005611
486 shares@ US$36.59940.0013% mcap50.0% of flowClass ASEC144:0001959173-26-005618
265 shares@ US$36.59940.0007% mcap50.0% of flowClass ASEC144:0001959173-26-005614
472 shares@ US$36.59940.0012% mcap50.0% of flowClass ASEC144:0001959173-26-005610
281,600 shares@ US$31.8741.9% of flowClass A Common StockSEC144:0001958244-26-000387
10,000 shares@ US$31.770.020% mcap48.0% of flowClass A Common StockSEC:0001104659-26-069604:0
Canonical exit: 27 Aug 2026 (T+90)
25 of 149 declarations
About Phibro Animal Health Corp
Phibro Animal Health Corp. (Nasdaq: PAHC) is a United States-listed company on the NASDAQ market, headquartered in Teaneck, New Jersey, United States. For French-speaking investors, Phibro fits the profile of a specialist animal-health and mineral-nutrition business, with exposure to end markets that are often relatively defensive, but still influenced by livestock cycles, feed costs, disease pressure and regional agricultural conditions.
The company develops, manufactures and markets a broad portfolio of products for food-producing and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. Its product set spans disease prevention and treatment solutions, medicated feed additives, water-soluble products, nutritional specialties, vaccines and certain ingredients also used in personal care, industrial chemical and chemical-catalyst applications. Phibro reports its operations across three segments: Animal Health, Mineral Nutrition and Performance Products.
Read moreShow less
Historically, the company traces its roots back many decades and has evolved from an industrial chemicals heritage into a focused animal-health platform. It has operated under the Phibro Animal Health Corporation name since 2003 and became a NASDAQ-listed public company in 2014. That history is important for investors because it shows a business model built through a combination of organic development, proprietary products and targeted acquisitions. The most significant recent strategic step was the completed acquisition on October 31, 2024, of Zoetis’s medicated feed additive portfolio and certain water-soluble products and related assets. That transaction expanded Phibro’s scale, broadened its product offering and increased its manufacturing footprint.
Phibro has a global commercial and manufacturing presence, with sales across a wide international footprint and production assets in the United States, Europe, Latin America and Asia. This geographic diversification gives the company access to major livestock markets and helps balance demand across regions. Competitive positioning is based on its combination of animal health, nutrition and performance products, along with its broad franchise in livestock-focused solutions and a growing companion-animal pipeline.
Recent developments have been material. In fiscal 2025 and into 2026, Phibro reported strong revenue and earnings growth, supported in part by the Zoetis acquisition integration and improved operating momentum. The company also announced new initiatives in 2025 in canine oral health, underscoring efforts to expand beyond traditional livestock categories. In late 2025, Phibro announced a leadership transition, indicating continued strategic evolution and execution focus. Overall, Phibro presents as a mid-sized but diversified animal-health platform with international reach, a long operating history and a recent acquisition-led growth phase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
